Please assess the completion status of the following clinical trial:

Trial Title: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing and able to comply with all trial requirements~* Subject is male or female and over 13 years of age~* Subject has a diagnosis of either TSC or NF1 and has visible fibromatous lesions (angiofibromas or neurofibromas)~* Female subjects of child-bearing potential must not be pregnant and must agree to use appropriate contraceptive methods for the duration of the trial~Exclusion Criteria:~* Subject is currently receiving therapy with rapamycin or sirolimus~* Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction~* Subject is currently participating in or has participated within the last 30 days in any clinical trial involving an investigational drug~* Subject has a known hypersensitivity to either the PVDF coating (Skincerity®) or rapamycin~* Subject is a pregnant or nursing female

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TSC Placebo Arm (Type: PLACEBO_COMPARATOR): TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
- TSC 1% Arm (Type: EXPERIMENTAL): TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
- TSC 5% Arm (Type: EXPERIMENTAL): TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
- NF1 Placebo Arm (Type: PLACEBO_COMPARATOR): NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
- NF1 1% Arm (Type: EXPERIMENTAL): NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
- NF1 5% Arm (Type: EXPERIMENTAL): NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas

Based on this trial design, predict the completion outcome and termination type (if applicable).